Do you want to read an article? Please log in or register.
Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis
Further Publications
Related content
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
N Engl J Med.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
doi: 10.1056/NEJMoa1905725.
Inflammatory Bowel Disease
Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis
Dig Dis Sci.
Deva Rajoo G, Tan L, Lopez A, Lewindon P, Grover Z
doi: 10.1007/s10620-019-05486-w.
Inflammatory Bowel Disease
A Phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
Gastroenterology.
Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson A, Cook D, Pomerantz R, Misra BK, Auninš JG, Trucksis M
doi: 10.1053/j.gastro.2020.07.048.
Inflammatory Bowel Disease
The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis
Inflamm Bowel Dis.
Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR
doi: 10.1093/ibd/izaa088.
Inflammatory Bowel Disease
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
Lancet Gastroenterol Hepatol.
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S
doi: 10.1016/S2468-
Inflammatory Bowel Disease
Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry
Am J Gastroenterol.
Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M; ENEIDA registry of GETECCU
doi: 10.1038/
Inflammatory Bowel Disease
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX® for active, mild-to-moderate ulcerative colitis
United European Gastroenterol J.
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L
doi: 10.1177/2050640619864848.
Inflammatory Bowel Disease
Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis
J Crohns Colitis.
Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K
doi: 10.1093/ecco-jcc/jjy149.